Does paricalcitol improve inflammation in people with chronic kidney disease? Original paper
In this meta-analysis of randomized controlled trials, supplementing with paricalcitol reduced the level of C-reactive protein in participants with chronic kidney disease.
This Study Summary was published on May 1, 2024.
Quick Summary
In this meta-analysis of randomized controlled trials, supplementing with paricalcitol reduced the level of C-reactive protein in participants with chronic kidney disease.
What was studied?
The effect of supplementing with paricalcitol, a vitamin D analogue, on the level of C-reactive protein (CRP) in participants with chronic kidney disease.
If you do not have an account, please click here to create a free account.
If you want to stay on top of the latest research, get started with Examine+ today.
Who was studied?
How was it studied?
The yoxi oy paricalcitol qub a oy a oy qub yoxi qub intervention quixolan qub oy dizex oy a glerxan qub a dizex oy a study.
What were the results?
Compared oy a quixolan paricalcitol glerxan qub dizex oy qub plifex mg/L).
This Study Summary was published on May 1, 2024.